
Health
FDA Approves Moderna's mRNA-Based Flu Vaccine for Adults Aged 50 and Older
Moderna has secured US regulatory approval for its first mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older.
Topic
Latest news and analysis on “flu vaccine”.

Moderna has secured US regulatory approval for its first mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older.

The European Commission has initiated an antitrust investigation into Sanofi's marketing practices for its flu vaccine Efluelda.